---
title: "Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Economic impact on families"
description: "Formulary evidence on Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Economic impact on families. Topics: Family quality of life and household expenses by disease activity and control, international UCARE study; Healthcare costs in Medicaid-enrolled children younger than 12 years; Healthcare costs in commercially insured children younger than 12 years. 3 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description/economic-impact-on-families"
published: "2026-11-18T22:38:31-05:00"
modified: "2026-11-18T22:38:31-05:00"
---

# Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Economic impact on families

<a id="heading-2.2.1.8.3"></a>

## 2.2.1.8.3 Economic Impact of Chronic spontaneous urticaria on Families

<a id="topic-2.2.1.8.3-1"></a>

### Family quality of life and household expenses by disease activity and control, international UCARE study

> “This international cross‐sectional study was conducted in 12 countries across three continents, from January to December 2024 at Urticaria Centres of Reference and Excellence (UCARE).”
> “A total of 1187 CSU patients and their respective family members completed questionnaires, including the Family Dermatology Life Quality Index (FDLQI), and physicians also provided clinical data on disease severity and control.”
> “FDLQI had a mean total score of 9.6 and mean scores varied across countries (Figure 1, Table S1).”
> “When stratified by UAS7 severity (minimal activity, mild, moderate, severe), family members of patients with higher disease activity reported significantly greater emotional distress, physical burden, social limitations and financial strain (Figure 3, Table S2).”
> “Household expenses showed no statistically significant association with either severity (β = 0.27; CI95% –0.47 to 1.00) or control (β = −0.23; CI95% –0.53 to 0.06).”

Source: [Abdalla et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13425259/)

<a id="topic-2.2.1.8.3-2"></a>

### Healthcare costs in Medicaid-enrolled children younger than 12 years

> “Medicaid claims from four states (09/01/2013–03/31/2016) were used to identify patients less than 12 years old.”
> “A total of 548 CIU/CSU patients (mean [SD] age 4.5 [3.3] years; 51.3% male) were matched 1:1 with controls.”
> “Moreover, CIU/CSU patients also had significantly higher PPPY healthcare costs (mean cost difference [MCD] $1853), driven by incremental outpatient (MCD $1286) costs (all p values < 0.01).”
> “CIU/CSU adversely affects lives of pediatric patients and their caregivers, leading to school absenteeism, reduced school performance, and more days off work [9].”

Source: [Williams et al. (2018a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5825330/)

<a id="topic-2.2.1.8.3-3"></a>

### Healthcare costs in commercially insured children younger than 12 years

> “To describe treatment patterns, health care resource utilization (HRU), and costs in pediatric patients with CIU/CSU (<12 years old) and to compare these with pediatric patients without CIU/CSU.”
> “A commercial administrative claims data base (September 2013 to June 2016) was used.”
> “A total of 6109 pediatric patients with CIU/CSU were selected, and 6107 were 1:1 matched with controls.”
> “Relative to the controls, the patients with CIU/CSU had higher rates of HRU (incidence rate ratios of 1.71, 2.39, and 2.07 for inpatient, emergency department, and outpatient visits, respectively; all p < 0.01), and higher all-cause per patient per year costs (mean cost differences of $2090, $1606, and $483 for total, medical, and pharmacy costs, respectively; all p < 0.01).”

Source: [Williams et al. (2018b)](https://pubmed.ncbi.nlm.nih.gov/29514728/)

## Related pages
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Terms and abbreviations](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations.md)
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Product information and disease description](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Clinical evidence](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Economic information and modeling report](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: References](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references.md)
